Journal
BIOCHEMICAL JOURNAL
Volume 479, Issue 4, Pages 463-477Publisher
PORTLAND PRESS LTD
DOI: 10.1042/BCJ20210280
Keywords
-
Categories
Funding
- Wellcome Trust [101794, 210634]
- BBSRC [BB/R007195/1]
- Ovarian Cancer Research Alliance (Collaborative Research Development Grant) [813369]
- Cancer Research UK [C35050/A22284]
- BBSRC [BB/R007195/1] Funding Source: UKRI
Ask authors/readers for more resources
ADP-ribosylation is a post-translational modification of proteins that plays a crucial role in cellular processes and microbial pathogenicity. Recent studies have revealed non-canonical forms of ADP-ribosylation, including modifications of nucleic acids and the discovery of new ADP-ribose derivatives. The physiological relevance of non-canonical ADP-ribosylation deserves recognition alongside traditional protein ADP-ribosylation modification.
ADP-ribosylation has primarily been known as post-translational modification of proteins. As signalling strategy conserved in all domains of life, it modulates substrate activity, localisation, stability or interactions, thereby regulating a variety of cellular processes and microbial pathogenicity. Yet over the last years, there is increasing evidence of non canonical forms of ADP-ribosylation that are catalysed by certain members of the ADPribosyltransferase family and go beyond traditional protein ADP-ribosylation signalling. New macromolecular targets such as nucleic acids and new ADP-ribose derivatives have been established, notably extending the repertoire of ADP-ribosylation signalling. Based on the physiological relevance known so far, non-canonical ADP-ribosylation deserves its recognition next to the traditional protein ADP-ribosylation modification and which we therefore review in the following.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available